Core Insights - The company, 来凯医药-B (02105), announced positive preliminary results from the Phase I Multiple Ascending Dose (MAD) study of LAE102 for obesity treatment in China [1][2] - The MAD study demonstrated safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered LAE102 in overweight/obese subjects [1] Group 1: Study Results - The MAD study included overweight/obese subjects with an average BMI of 29.4 kg/m² and involved three dosing groups (2 mg/kg, 4 mg/kg, and 6 mg/kg) administered weekly for four weeks [1] - In the 6 mg/kg dosing group, subjects showed an average lean body mass increase of 1.7% and a fat mass reduction of 2.2% by week 5 [1] - After adjusting for the placebo group, the average lean body mass increase reached 4.6%, while fat mass decreased by 3.6% [1] Group 2: Safety and Tolerability - The MAD study confirmed good tolerability and safety, with no serious adverse events reported [1] - Most adverse events during treatment were mild (Grade 1) laboratory abnormalities, with no cases of diarrhea, muscle cramps, or acne reported [1] - Safety results were consistent with previous findings from the single ascending dose (SAD) study, with no new safety signals observed [1] Group 3: Future Development and Partnerships - The positive results from the MAD study support the continued clinical development of LAE102 for obesity treatment [2] - The company is actively negotiating with potential partners who have serious commitments and financial strength to prioritize this project, aiming to accelerate clinical development and commercialization [2] - The company maintains a robust financial position, allowing for selective evaluation of potential partnership structures to maximize global asset potential [2]
来凯医药-B(02105)：I期临床MAD研究取得积极初步结果 LAE102展现出令人鼓舞的增肌减脂趋势